 Connection
Michael Birrer to MAP Kinase Kinase Kinases
This is a "connection" page, showing publications Michael Birrer has written about MAP Kinase Kinase Kinases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.258 |
|
|
|
-
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428.
Score: 0.173
-
Farley J, Ozbun L, Samimi G, Birrer MJ. Cell cycle and related protein. Dis Markers. 2007; 23(5-6):433-43.
Score: 0.071
-
Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A, Tzivion G. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem. 2003 Jul 18; 278(29):26715-21.
Score: 0.014
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|